Fig. 3.

Fatigue severity level transition from double-blind baseline to Week 12. n = number of patients with at least one fatigue severity level improvement. Nsub number of patients with available information at the timepoint. Percentages are based on Nsub. OR calculated using CMH test with no stratification variables. Patients with “missing” Neuro-QoL Short Form Fatigue data at baseline excluded. The statistical analysis includes patients with baseline and Week 12 data who had a potential to improve (2 patients in the zilucoplan group reported “no problems” at baseline and were excluded from this analysis). BL baseline, CI confidence interval, CMH Cochran–Mantel–Haenszel, OR odds ratio